# A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Source: https://onco.cc/trials/nct06317311/  
OnCo record `nct06317311` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dostarlimab and Carboplatin in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06317311 by GlaxoSmithKline, with 41 participants enrolled, started 2024-05-07 and due to reach its primary completion in 2026-07-15. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06317311
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)
- Sponsor: GlaxoSmithKline
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT06317311: https://clinicaltrials.gov/study/NCT06317311

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06317311.json